C4 Therapeutics Stock Buy Hold or Sell Recommendation
| CCCC Stock | USD 2.03 0.01 0.50% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding C4 Therapeutics is 'Cautious Hold'. Macroaxis provides C4 Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CCCC positions.
Check out C4 Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide. In addition, we conduct extensive research on individual companies such as CCCC and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
CCCC |
Execute C4 Therapeutics Buy or Sell Advice
The CCCC recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on C4 Therapeutics. Macroaxis does not own or have any residual interests in C4 Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute C4 Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
C4 Therapeutics Trading Alerts and Improvement Suggestions
| C4 Therapeutics generated a negative expected return over the last 90 days | |
| C4 Therapeutics has high historical volatility and very poor performance | |
| C4 Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 35.58 M. Net Loss for the year was (105.32 M) with loss before overhead, payroll, taxes, and interest of (75.05 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (65.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: C4 Therapeutics stock hits 52-week low at 2.21 - Investing.com India |
C4 Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CCCC analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CCCC analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
C4 Therapeutics Returns Distribution Density
The distribution of C4 Therapeutics' historical returns is an attempt to chart the uncertainty of C4 Therapeutics' future price movements. The chart of the probability distribution of C4 Therapeutics daily returns describes the distribution of returns around its average expected value. We use C4 Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of C4 Therapeutics returns is essential to provide solid investment advice for C4 Therapeutics.
| Mean Return | -1.07 | Value At Risk | -8.28 | Potential Upside | 7.10 | Standard Deviation | 4.47 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of C4 Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
CCCC Stock Institutional Investors
| Shares | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 1.3 M | State Street Corp | 2024-12-31 | 1.2 M | Silverarc Capital Management, Llc | 2024-12-31 | 1.2 M | Bain Capital Life Sciences Investors, Llc | 2024-12-31 | 1.1 M | Tang Capital Management Llc | 2024-12-31 | 900 K | Two Sigma Advisers, Llc | 2024-12-31 | 884.3 K | Ubs Group Ag | 2024-12-31 | 757.9 K | Goldman Sachs Group Inc | 2024-12-31 | 573.7 K | Two Sigma Investments Llc | 2024-12-31 | 563.8 K | Soleus Capital Management, L.p. | 2024-12-31 | 7 M | Wasatch Advisors Lp | 2024-12-31 | 6.1 M |
C4 Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (190.5M) | (188.1M) | 58.4M | 135.7M | (51.3M) | (53.8M) | |
| Change In Cash | 91.2M | (104.9M) | (46.4M) | 97M | (71.1M) | (67.5M) | |
| Free Cash Flow | (67.9M) | (88.2M) | (111.4M) | (108.5M) | (65.3M) | (68.6M) | |
| Depreciation | 1.6M | 1.5M | 1.7M | 1.9M | 1.8M | 1.8M | |
| Other Non Cash Items | 1.6M | 2.1M | 7.3M | 3.5M | 6.4M | 3.9M | |
| Capital Expenditures | 650K | 1.3M | 5.5M | 1.7M | 180K | 171K | |
| Net Income | (66.3M) | (83.9M) | (128.2M) | (132.5M) | (105.3M) | (110.6M) | |
| End Period Cash Flow | 184.3M | 79.4M | 33.0M | 130.0M | 58.9M | 70.6M | |
| Change To Netincome | 2.0M | 10.2M | 21.5M | 30.0M | 34.5M | 36.2M |
C4 Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to C4 Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that C4 Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a CCCC stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.81 | |
β | Beta against Dow Jones | 2.49 | |
σ | Overall volatility | 4.29 | |
Ir | Information ratio | -0.22 |
C4 Therapeutics Volatility Alert
C4 Therapeutics exhibits very low volatility with skewness of 0.19 and kurtosis of -0.2. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure C4 Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact C4 Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.C4 Therapeutics Fundamentals Vs Peers
Comparing C4 Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze C4 Therapeutics' direct or indirect competition across all of the common fundamentals between C4 Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as C4 Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of C4 Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare C4 Therapeutics to competition |
| Fundamentals | C4 Therapeutics | Peer Average |
| Return On Equity | -0.46 | -0.31 |
| Return On Asset | -0.2 | -0.14 |
| Profit Margin | (2.96) % | (1.27) % |
| Operating Margin | (7.28) % | (5.51) % |
| Current Valuation | (35.75 M) | 16.62 B |
| Shares Outstanding | 70.99 M | 571.82 M |
| Shares Owned By Insiders | 11.51 % | 10.09 % |
| Shares Owned By Institutions | 91.51 % | 39.21 % |
| Number Of Shares Shorted | 8.06 M | 4.71 M |
| Price To Book | 0.66 X | 9.51 X |
| Price To Sales | 4.05 X | 11.42 X |
| Revenue | 35.58 M | 9.43 B |
| Gross Profit | (75.05 M) | 27.38 B |
| EBITDA | (115.36 M) | 3.9 B |
| Net Income | (105.32 M) | 570.98 M |
| Cash And Equivalents | 307.78 M | 2.7 B |
| Cash Per Share | 6.29 X | 5.01 X |
| Total Debt | 133.62 M | 5.32 B |
| Debt To Equity | 0.25 % | 48.70 % |
| Current Ratio | 6.90 X | 2.16 X |
| Book Value Per Share | 3.06 X | 1.93 K |
| Cash Flow From Operations | (65.16 M) | 971.22 M |
| Short Ratio | 4.70 X | 4.00 X |
| Earnings Per Share | (1.52) X | 3.12 X |
| Price To Earnings To Growth | 0.07 X | 4.89 X |
| Target Price | 15.56 | |
| Number Of Employees | 110 | 18.84 K |
| Beta | 3.0 | -0.15 |
| Market Capitalization | 144.11 M | 19.03 B |
| Total Asset | 349.6 M | 29.47 B |
| Retained Earnings | (633.7 M) | 9.33 B |
| Working Capital | 212.59 M | 1.48 B |
| Current Asset | 1 K | 9.34 B |
Note: Disposition of 669 shares by Boyle Scott N of C4 Therapeutics at 3.15 subject to Rule 16b-3 [view details]
C4 Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as CCCC . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About C4 Therapeutics Buy or Sell Advice
When is the right time to buy or sell C4 Therapeutics? Buying financial instruments such as CCCC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having C4 Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Commodities ETFs Thematic Idea Now
Broad Commodities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Commodities ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Commodities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out C4 Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth 0.588 | Return On Assets | Return On Equity |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.